4.5 Article

Prospective study of fertility-sparing treatment with chlormadinone acetate for endometrial carcinoma and atypical hyperplasia in young women

期刊

出版社

WILEY
DOI: 10.1002/ijgo.13941

关键词

atypical hyperplasia; chlormadinone acetate; endometrial carcinoma; fertility-sparing treatment

向作者/读者索取更多资源

The study confirms that the use of chlormadinone acetate for 6 months is comparable to other fertility-sparing treatments in achieving remission of atypical hyperplasia or endometrial carcinoma. It is an effective and well-tolerated treatment option, with the added benefit of allowing some patients to achieve live births.
Objective To confirm that the efficiency of the use of chlormadinone acetate for 6 months to obtain remission of atypical hyperplasia or endometrial carcinoma is comparable to that of the use of other fertility-sparing treatments. Method The present study is based on the PREFERE prospective registry. All the patients received 3 or 6 months of chlormadinone acetate and were evaluated by hysteroscopic resection and pipelle sampling every 3 months. Results Ninety-four patients were included. Seventy-nine patients achieved complete remission at 6 months (84%). No patients stopped treatment because of a lack of tolerance. Twenty-four per cent of the patients achieved a live birth. Conclusion Chlormadinone acetate is an effective and well-tolerated fertility-sparing treatment. Its benefits over other progestins are its tolerability, and its absence of contraindications, which make it a good choice for patients with thromboembolism and high vascular risk.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据